Diseases of the Endocrine System, Phase II

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Volunteers
Health Professionals

What is the purpose of this trial?

The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of hypertriglyceridemia (HTG)-associated acute pancreatitis (AP) who experience a recurrent episode of AP after treatment with evinacumab versus placebo.

Trial with
Regeneron Pharmaceuticals, Inc.
Ages
18 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Elizabeth Szymanski

beth.szymanski@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Thiruvengadam Muniraj, MD, FACG, FRCP
Associate Professor of Medicine (Digestive Diseases); Vice-Chief for Endoscopy, Digestive Diseases; Director of Advanced Endoscopy, YNHHS; Associate Chief of Endoscopy, Digestive Health; Director, Yale Center for Pancreatitis; Director, Bariatric Endoscopy

Sub-Investigators

Last Updated
05/11/2023
Study HIC
#2000031006